Antimicrobial therapy for bone and joint infections

Aslam, Saima; Darouiche, Rabih O.

doi:10.1007/s11908-009-0002-x

Cited by 14 publications

(16 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The treatment of chronic osteomyelitis is more complicated and requires a multidisciplinary approach in 3 phases: surgical debridement, systemic antibiotic therapy for 4 to 6 weeks and local antibiotic delivery systems (Sánchez et al, 2001;Aslam, Darouiche, 2009;Mouzopoulos, 2011). The goal of surgical treatment is to convert an infection with dead bone to a situation with well-vascularized tissues that are readily penetrated by antibiotics, making prolonged drug treatment unnecessary (Mader et al, 1993).…”

Section: General Considerationsmentioning

confidence: 99%

“…In addition, the widespread use of quinolones has led to the emergence of quinolone-resistant S. aureus strains (Pawar, Bhandari, 2011), therefore the use of a second agent in the treatment of S. aureus infection is advisable (Darley, MacGowan, 2004). Fluoroquinolones have also been reported to inhibit fracture healing, but the clinical significance of this observation is not known (Aslam, Darouiche, 2009). …”

Section: Fluoroquinolonesmentioning

confidence: 99%

“…Rifampicin, a broad-spectrum antimicrobial agent, achieves high intracellular levels and is one of the few antimicrobial agents that can penetrate biofilms and kill organisms in the sessile phase of growth (Aslam, Darouiche, 2009). Several studies have shown that oral treatment with rifampicin in combination with various antibiotics as ciprofloxacin, ofloxacin, or fusidic acid is effective in bone staphylococcal infections in the presence of implants or prosthetic joints (Lew, Waldvogel, 2004;Pawar, Bhandari, 2011).…”

Section: Rifampicin and Fusidic Acidmentioning

confidence: 99%

“…Like rifampicin, early development of resistance, is one of the prime limitations of fusidic acid, unless used in combination (Pawar, Bhandari, 2011). Rifampicin and fusidic acid are reasonable adjunctive agents for combination therapy (Aslam, Darouiche, 2009). …”

Section: Rifampicin and Fusidic Acidmentioning

confidence: 99%

“…Newer antibiotics with high bone penetration such as linezolid, daptomycin and tigecycline are promising for treating osteomyelitis due to MRSA in patients who display intolerance or poor response to vancomycin but must be further tested in clinical trials Aslam, Darouiche, 2009;Pawar, Bhandari, 2011). A good review on the topic was recently published by Pawar and Bhandari (2011).…”

Section: New Agentsmentioning

confidence: 99%

See 4 more Smart Citations

Osteomyelitis: an overview of antimicrobial therapy

Gomes

Pereira

Bettencourt

2013

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Osteomyelitis is an inflammatory bone disorder caused by infection, leading to necrosis and destruction of bone. It can affect all ages, involve any bone, become a chronic disease and cause persistent morbidity. Treatment of osteomyelitis is challenging particularly when complex multiresistant bacterial biofilm has already been established. Bacteria in biofilm persist in a low metabolic phase, causing persistent infection due to increased resistance to antibiotics. Staphylococcus aureus and Staphylococcus epidermidis are the most common causative organism responsible for more than 50% of osteomyelitis cases. Osteomyelitis treatment implies the administration of high doses of antibiotics (AB) by means of endovenous and oral routes and should take a period of at least 6 weeks. Local drug delivery systems, using non-biodegradable (polymethylmethacrylate) or biodegradable and osteoactive materials such as calcium orthophosphates bone cements, have been shown to be promising alternatives for the treatment of osteomyelitis. These systems allow the local delivery of AB in situ with bactericidal concentrations for long periods of time and without the toxicity associated with other means of administration. This review examines the most recent literature evidence on the causes, pathogeneses and pharmacological treatment of osteomyelitis. A osteomielite é um processo inflamatório do tecido ósseo, de origem infecciosa, que resulta em destruição inflamatória, necrose e formação de novo osso. Pode aparecer em qualquer idade, afetar qualquer osso e tornar-se uma doença crônica com morbidade persistente. Apesar dos progressos na quimioterapia infecciosa, o tratamento da osteomielite é caro e difícil, em particular quando associada à presença de biofilmes bacterianos, especialmente de Staphylococcus aureus e Staphylococcus epidermidis. O tratamento da osteomielite inclui a administração de doses elevadas de antibióticos (AB) por via endovenosa e oral, durante um período de pelo menos 6 semanas. Os sistemas de veiculação localizada de fármacos, utilizando materiais não biodegradáveis (polimetilmetacrilato) ou biodegradáveis e osteoativos como os cimentos ósseos de ortofosfatos de cálcio e vidro bioativo, surgiram como uma alternativa promissora para o tratamento da osteomielite. Estes sistemas permitem a veiculação de AB in situ com concentrações bactericidas por longos períodos de tempo e sem a toxicidade associada às outras vias de administração. O presente trabalho propõe uma revisão da literatura relativa às causas, à patogenia e ao tratamento farmacológico da osteomielite. A metodologia do estudo da revisão consistiu numa pesquisa bibliográfica, nas bases de dados Google Scholar, Science Direct, Pubmed, Springer link, B-on. Foram revistos e analisados diversos artigos publicados desde o ano de 1979.Unitermos: Osteomielite/tratamento farmacológico. Osteomielite/terapia antimicrobial. Staphylococcus aureus/presença/osteomielite. Antibióticos/uso/tratamento da osteomielite.

show abstract

Section: General Considerationsmentioning

confidence: 99%

Section: Fluoroquinolonesmentioning

confidence: 99%

Section: Rifampicin and Fusidic Acidmentioning

confidence: 99%

Section: Rifampicin and Fusidic Acidmentioning

confidence: 99%

Section: New Agentsmentioning

confidence: 99%

See 3 more Smart Citations

Osteomyelitis: an overview of antimicrobial therapy

Gomes

Pereira

Bettencourt

2013

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

Tetracycline tethered to titanium inhibits colonization by Gram‐negative bacteria

et al. 2014

View full text Add to dashboard Cite

As peri-prosthetic infection is one of the most devastating complications associated with implant placement, we have reasoned that such infection can be largely subverted by development of antibacterial implants. Our previous work demonstrated that covalent coupling of vancomycin to titanium alloy prevented colonization by the gram-positive pathogens, Staphylococcus aureus and Staphylococcus epidermidis. Some orthopaedic devices, including permanent prosthesis anchors, and most dental implants are transcutaneous or transmucosal and can be prone to colonization by Gram-negative pathogens. We report here the successful covalent coupling of the broad-spectrum antibiotic, tetracycline (TET), to titanium surfaces (Ti-TET) to retard Gram-negative colonization. Synthetic progress was followed by changes in water contact angle, while the presence of TET was confirmed by immunofluorescence. Ti-TET actively prevented colonization in the presence of bathing Escherichia coli, both by fluorescence microscopy and direct counting. Finally, the Ti-TET surface supported osteoblastic cell adhesion and proliferation over a 72 hour period. Thus, this new surface offers a powerful means to protect transcutaneous implants from adhesion of Gram-negative pathogens, decreasing the need for replacement of this hardware.

show abstract

An antibiofilm coating of 5‐aryl‐2‐aminoimidazole covalently attached to a titanium surface

et al. 2018

View full text Add to dashboard Cite

Biofilms, especially those formed by Staphylococcus aureus, play a key role in the development of orthopedic implant infections. Eradication of these infections is challenging due to the elevated tolerance of biofilm cells against antimicrobial agents. In this study, we developed an antibiofilm coating consisting of 5-(4-bromophenyl)-N-cyclopentyl-1-octyl-1H-imidazol-2-amine, designated as LC0024, covalently bound to a titanium implant surface (LC0024-Ti). We showed in vitro that the LC0024-Ti surface reduces biofilm formation of S. aureus in a specific manner without reducing the planktonic cells above the biofilm, as evaluated by plate counting and fluorescence microscopy. The advantage of compounds that only inhibit biofilm formation without affecting the viability of the planktonic cells, is that reduced development of bacterial resistance is expected. To determine the antibiofilm activity of LC0024-Ti surfaces in vivo, a biomaterial-associated murine infection model was used. The results indicated a significant reduction in S. aureus biofilm formation (up to 96%) on the LC0024-Ti substrates compared to pristine titanium controls. Additionally, we found that the LC0024-Ti substrates did not affect the attachment and proliferation of human cells involved in osseointegration and bone repair. In summary, our results emphasize the clinical potential of covalent coatings of LC0024 on titanium implant surfaces to reduce the risk of orthopedic implant infections.

show abstract

Antimicrobial therapy for bone and joint infections

Cited by 14 publications

References 51 publications

Osteomyelitis: an overview of antimicrobial therapy

Osteomyelitis: an overview of antimicrobial therapy

Tetracycline tethered to titanium inhibits colonization by Gram‐negative bacteria

An antibiofilm coating of 5‐aryl‐2‐aminoimidazole covalently attached to a titanium surface

Contact Info

Product

Resources

About